Australia markets closed

ContraFect Corporation (CFRX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0700-0.2700 (-8.08%)
At close: 04:00PM EDT
3.4200 +0.35 (+11.40%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3400
Open3.3500
Bid3.0300 x 3100
Ask3.4200 x 1000
Day's range3.0200 - 3.4250
52-week range2.1100 - 4.7550
Volume85,400
Avg. volume125,362
Market cap120.751M
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)-0.8950
Earnings date11 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • GlobeNewswire

    Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

    YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase, which has been designated as a Breakthrough Therapy for developm

  • GlobeNewswire

    ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

    YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The

  • GlobeNewswire

    Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

    Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinic